Combined treatment with pemetrexed and vinflunine in patients with metastatic urothelial cell carcinoma after prior platinum-containing chemotherapy - results of an exploratory phase I study

Autor: Anders Ullén, H. von der Maase, Mads Agerbæk, Helle Pappot

Publikováno v: Pappot, H, von der Maase, H, Ullén, A, Agerbæk, M & NUCOG-Nordic Urothelial Cancer Oncology Group (NUCOG) 2018, ' Combined treatment with pemetrexed and vinflunine in patients with metastatic urothelial cell carcinoma after prior platinum-containing chemotherapy-results of an exploratory phase I study ', Investigational New Drugs, vol. 36, no. 4, pp. 615-618 . https://doi.org/10.1007/s10637-017-0528-y

Vinflunine is to date the only registered agent for second-line treatment of metastatic urothelial cell carcinoma (UCC) in Europe. However, the effect is modest. Pemetrexed has demonstrated some single-agent activity in this disease entity. In order

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::da6979b8bbdf89198b129d5467b43fcf
https://pubmed.ncbi.nlm.nih.gov/29081023

Bacillus Calmette-Guérin strain differences have an impact on clinical outcome in bladder cancer immunotherapy

Autor: Alexander Bachmann, Aurélie Bisiaux, Roland Brosch, Molly A. Ingersoll, Frédéric D. Birkhäuser, Gilles Marchal, Micheline Lagranderie, Mickael Orgeur, Joel R. Gsponer, Christian Wetterauer, Cyrill A. Rentsch, Matthew L. Albert, Christiane Bouchier, Claire Biot, George N. Thalmann

Publikováno v: European Urology
European Urology, Elsevier, 2014, 66 (4), pp.677-688. ⟨10.1016/j.eururo.2014.02.061⟩
European Urology, 2014, 66 (4), pp.677-688. ⟨10.1016/j.eururo.2014.02.061⟩
Eur Urol

BACKGROUND: Whether the commonly used bacillus Calmette-Guerin (BCG) strains Connaught and Tice confer different treatment responses in non-muscle-invasive bladder cancer (NMIBC) is unknown. OBJECTIVES: To compare clinical efficacy, immunogenicity, a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5ff25b2981c709a330c86d4b82b4317a
https://pubmed.ncbi.nlm.nih.gov/25760254

Chemotherapy of metastatic urothelial carcinoma. cis-Diamminedichloroplatinum combination chemotherapy for patients with decreased renal function

Autor: Kihara, Kazunori, Kusuyama, Hiroyuki, Washizuka, Makoto, Kawai, Tsuneo

Publikováno v: 泌尿器科紀要. 30(1):21-28

1) CDDPを用いた例の腎機能変化を検討し, 低腎機能例(Ccr
Cis-diamminedichloroplatinum (CDDP) combination chemotherapy has induced a high response rate in the treatment of metastatic urothelial carcinoma at our clinic. However, d

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=jairo_______::17bdff757e4603b1922a6f78ad57f661
http://hdl.handle.net/2433/118098

Treatment of tumors of the urinary bladder with so-called immunopotentiators

Autor: Tsujimura, Shunsaku, Kato, Jiro, Ueda, Kosuke, Ohtaguro, Kazuo

Publikováno v: 泌尿器科紀要. 29(1):9-15

Eighty-eight cases of urinary bladder tumor were treated in our Department from 1976 to 1978. The effect of so-called immunopotentiators (OK-432, Levamisole and PSK) was studied in 23 patients. The following results were obtained. Pretreatment intrac

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=jairo_______::60a365d4a19eea1d4db0628c4b186cab
http://hdl.handle.net/2433/120107

膀胱癌, 腎細胞癌に対するUFTの使用経験

Autor: Nakagami, Yoshizo, Lin, Tsaw Tung, Ito, Hiroshi, Hirasawa, Seiichi, Tannawa, Kunio, Fujioka, Yoshiaki, Ogawa, Hideya, Tanaka, Kyuhei, Yamada, Norimichi, Ishii, Yoji, Hikima, Norio

Publikováno v: 泌尿器科紀要. 33(10):1728-1732

The safety of prolonged administration of UFT in which tegafur and uracil were mixed in a ratio of 1:4 in molar fraction was studied in 44 cases of bladder cancer and 10 cases of renal cell carcinoma. Daily doses of UFT were 300-600 mg, and average t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=jairo_______::61839428443dd9c2aa4209502ac33dfd
http://hdl.handle.net/2433/119290